Nuwellis reports Q3 EPS $1.74 vs ($63.27) last year

Reports Q3 revenue $2.367M vs $2.412M last year. “We commend the hard work and dedication of the Nuwellis (NUWE) team, fueling steady market adoption of our Aquadex ultrafiltration therapy, with revenue in the third quarter 2024 led by console sales and new account wins in our Pediatric customer category, which posted 28% annual growth,” said Nestor Jaramillo, President and CEO of Nuwellis. “We continue to see momentum with new accounts steadily opening on increasing awareness of the efficacy and supporting clinical evidence for Aquadex ultrafiltration therapy in the adult and pediatric customer categories. We believe these newly published clinical results will have a positive impact in growing our business and supporting Aquadex in becoming the standard of care for fluid removal when diuretics are ineffective. Following the closing of the quarter, we received notice of a 297% increase to $1,639 per day in reimbursement from the Centers for Medicare and Medicaid Services which greatly expands the outpatient marketplace for fluid removal. This reimbursement increase is effective January 1, 2025.”